532 related articles for article (PubMed ID: 19878590)
41. Are Seretide and Symbicort useful in COPD?
Drug Ther Bull; 2004 Mar; 42(3):18-21. PubMed ID: 15038079
[TBL] [Abstract][Full Text] [Related]
42. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Cates CJ; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2004; (3):CD003794. PubMed ID: 15266502
[TBL] [Abstract][Full Text] [Related]
43. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
Papi A; Jones PW; Dalvi PS; McAulay K; McIver T; Dissanayake S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2431-8. PubMed ID: 26648706
[TBL] [Abstract][Full Text] [Related]
44. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
45. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
47. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
Saito T; Takeda A; Hashimoto K; Kobayashi A; Hayamizu T; Hagan GW
Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737
[TBL] [Abstract][Full Text] [Related]
48. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.
Halpin DM; Gray J; Edwards SJ; Morais J; Singh D
Int J Clin Pract; 2011 Jul; 65(7):764-74. PubMed ID: 21676119
[TBL] [Abstract][Full Text] [Related]
49. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.
Lasserson TJ; Ferrara G; Casali L
Cochrane Database Syst Rev; 2011 Dec; (12):CD004106. PubMed ID: 22161385
[TBL] [Abstract][Full Text] [Related]
50. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
Cope S; Kraemer M; Zhang J; Capkun-Niggli G; Jansen JP
Int J Chron Obstruct Pulmon Dis; 2012; 7():415-20. PubMed ID: 22848154
[TBL] [Abstract][Full Text] [Related]
52. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
Huang TM; Kuo KC; Wang YH; Wang CY; Lai CC; Wang HC; Chen L; Yu CJ;
BMC Infect Dis; 2020 Sep; 20(1):706. PubMed ID: 32977747
[TBL] [Abstract][Full Text] [Related]
53. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
54. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study.
Aalbers R; Brusselle G; McIver T; Grothe B; Bodzenta-Lukaszyk A
Adv Ther; 2012 Nov; 29(11):958-69. PubMed ID: 23081745
[TBL] [Abstract][Full Text] [Related]
55. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions.
Borgström L; Asking L; Lipniunas P
J Aerosol Med; 2005; 18(3):304-10. PubMed ID: 16181005
[TBL] [Abstract][Full Text] [Related]
56. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).
Janson C; Larsson K; Lisspers KH; Ställberg B; Stratelis G; Goike H; Jörgensen L; Johansson G
BMJ; 2013 May; 346():f3306. PubMed ID: 23719639
[TBL] [Abstract][Full Text] [Related]
57. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
[TBL] [Abstract][Full Text] [Related]
58. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
59. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life.
Price DB; Williams AE; Yoxall S
Respir Res; 2007 Jul; 8(1):46. PubMed ID: 17610727
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
